Legato Capital Management’s Tonix Pharmaceuticals TNXP Stock Holding History

Legato Capital Management’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$710K	Buy	+55,620	New	+$718K	0.06%	452

Other funds holding TNXP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

SIC

SJS Investment Consulting Sylvania, Ohio $919M AUM 23.4% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

LSA

Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return

Legato Capital Management's TNXP Position: Q2 2026 in Review

Legato Capital Management opened a new position in Tonix Pharmaceuticals (TNXP) in Q2 2026: 55,620 shares worth $710K. The stake represents 0.06% of the portfolio and ranks #452 among its holdings.

31 funds tracked by Wall St. Rank hold TNXP as of Q2 2026.

Legato Capital Management held 55,620 shares of Tonix Pharmaceuticals worth $710K as of Q2 2026.
Tonix Pharmaceuticals was a new Legato Capital Management position in Q2 2026.
Tonix Pharmaceuticals made up 0.06% of Legato Capital Management's portfolio in Q2 2026, its #452 holding.
31 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.